CEO Dr. Stephen
Schwartz to Retire; Search Underway to Identify
Successor
BURLINGTON, Mass., May 8, 2024
/PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a CEO
succession plan, under which CEO and Board Director Dr.
Stephen Schwartz will be retiring
from Azenta after more than 14 years of service. Dr. Schwartz will
continue to serve as CEO until a successor is appointed to ensure a
smooth transition.
Dr. Schwartz's retirement follows a discussion with the Board as
part of the company's active succession planning process. In
connection with that process, the Board has initiated a search to
identify Azenta's next CEO, and has engaged Heidrick &
Struggles, a leading executive search firm, to assist in the
process of identifying and evaluating candidates.
Dr. Schwartz said, "It has been a privilege to be a part of this
incredible company. I am proud of Azenta's achievements and I
want to express my deepest gratitude to the terrific Azenta team.
Together, we have undergone an impressive and complex
transformation from semiconductor capital equipment company, Brooks
Automation, to the leading life sciences business Azenta is today.
I look forward to supporting a smooth transition to the next CEO as
Azenta prepares to embark on its next chapter."
Frank E. Casal, Chair of the Board, said "On behalf of the
Board, we are grateful to Steve for his unwavering commitment to
Azenta for more than 14 years. Under his leadership and vision,
Azenta successfully transformed into a standalone, publicly-traded,
pure-play life sciences company, operating around the world with
annual revenue of over $600 million
and more than 3,000 team members. We thank Steve for his many
contributions to Azenta's success, his collaborative partnership in
the Boardroom as well as his commitment to leading the business, as
we identify the best possible successor."
Today, Azenta also reported its earnings results for the
second quarter of fiscal 2024.
About Dr. Stephen
Schwartz
Dr. Stephen Schwartz joined
Azenta in April 2010 as President and
was appointed CEO in August 2010.
During his tenure as CEO of Azenta, Dr, Schwartz oversaw the
$3 billion sale of Azenta's
Semiconductor Solutions business to Thomas H. Lee Partners, and
established Azenta as a global, pure-play life sciences company
with annual revenue of over $600
million. From November 2018 to
January 2024, Dr. Schwartz served on
the board of directors of Spire Inc., a publicly traded natural gas
company. Dr. Schwartz received his BSEE, MSEE, and Ph.D. in
electrical engineering from Purdue
University. He also holds an MBA from the University of Chicago.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life
sciences solutions worldwide, enabling impactful breakthroughs and
therapies to market faster. Azenta provides a full suite of
reliable cold-chain sample management solutions and multiomics
services across areas such as drug development, clinical research
and advanced cell therapies for the industry's top pharmaceutical,
biotech, academic and healthcare institutions globally. Our global
team delivers and supports these products and services through our
industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude,
Limfinity, Freezer Pro, Barkey and B Medical Systems.
Azenta is headquartered in Burlington,
MA, with operations in North
America, Europe and
Asia. For more information, please
visit www.azenta.com.
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial, Planning & Analysis and Investor
Relations
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
MEDIA CONTACTS:
Robin Weinberg, Emily Claffey
Azenta@fgsglobal.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/azenta-announces-ceo-succession-plan-302140301.html
SOURCE Azenta